An ultrasensitive DNA-enhanced amplification method for detecting cfDNA drug-resistant mutations in non-small cell lung cancer with selective FEN-assisted degradation of dominant somatic fragments.

Abstract excerpt

OBJECTIVES: Blood cell-free DNA (cfDNA) can be a new reliable tool for detecting epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) patients. However, the currently reported cfDNA assays have a limited role in detecting drug-resistant mutations due to their deficiencies in sensitivity, stability, or mutation detection rate. METHODS: We developed an Archaeoglobus...

Topics

Join the communities discussing this publication.

• Carcinoma, Non-Small-Cell Lung
• Cell-Free Nucleic Acids
• Drug Resistance, Neoplasm
• ErbB Receptors
• Flap Endonucleases